

Resource Summary Report

Generated by PRECISE-TBI on Sep 5, 2026

Anti-LRRK2 antibody [MJFF2 (c41-2)]

RRID:AB_2713963

Type: Antibody

Proper Citation

Abcam Cat# ab133474, RRID:AB_2713963

Antibody Information

URL: http://antibodyregistry.org/AB_2713963

Proper Citation: Abcam Cat# ab133474, RRID:AB_2713963

Target Antigen: LRRK2

Host Organism: rabbit

Clonality: monoclonal

Comments: Image validation available for WB, IHC-P, ICC/IF in MDS.

Antibody Name: Anti-LRRK2 antibody [MJFF2 (c41-2)]

Description: This monoclonal targets LRRK2

Target Organism: rat, mouse, human

Clone ID: MJFF2 (c41-2)

Antibody ID: AB_2713963

Vendor: Abcam

Catalog Number: ab133474

Record Creation Time: 20231110T033813+0000

Record Last Update: 20260829T010230+0000

Ratings and Alerts

- Head-to-head comparison of available commercial antibodies against Leucine-rich repeat kinase 2 (LRRK2) by immunoblot (Western blot), immunoprecipitation and immunofluorescence. - YCHarOS <https://ycharos.com/>

No alerts have been found for Anti-LRRK2 antibody [MJFF2 (c41-2)] .

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 30 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Fricke M, et al. (2026) Knockout of the LRRK2-counteracting RAB phosphatase PPM1H disrupts axonal autophagy and exacerbates alpha-synuclein aggregation. Cell reports, 45(6), 117364.

Karmali N, et al. (2026) Single-cell RNA profiling of oligodendroglial lineage cells derived from iPSCs carrying Parkinson's disease-relevant LRRK2-G2019S mutation. iScience, 29(7), 116368.

Qin Y, et al. (2026) Targeting leucine-rich repeat kinase 2 overcomes resistance to oncolytic herpes simplex virus-based therapies in glioblastoma. Nature communications, 17(1).

Goldman A, et al. (2026) An LRRK2 variant blocks NCOA4 trafficking upon iron overload, leading to ferroptotic death. Journal of cell science, 139(14).

Bogacki EC, et al. (2025) GPNMB is a biomarker for lysosomal dysfunction and is secreted via LRRK2-modulated lysosomal exocytosis. Science advances, 11(51), eadv1434.

Raig ND, et al. (2025) Type-II kinase inhibitors that target Parkinson's Disease-associated LRRK2. bioRxiv : the preprint server for biology.

Raig ND, et al. (2025) Type II kinase inhibitors that target Parkinson's disease-associated LRRK2. Science advances, 11(23), eadt2050.

Jong HL, et al. (2025) Generation of Leucine-Rich Repeat Kinase 2 (LRRK2) Knockout Neuroblastoma Cells SH-SY5Y by CRISPR/Cas9-Mediated Genome Editing. Biochemical genetics.

Pei J, et al. (2025) Lrrk2 G2019S mutation incites increased cell-intrinsic neutrophil effector functions and intestinal inflammation in a model of infectious colitis. NPJ Parkinson's disease, 11(1), 267.

Abe T, et al. (2024) Lysosomal stress drives the release of pathogenic α -synuclein from macrophage lineage cells via the LRRK2-Rab10 pathway. iScience, 27(2), 108893.

- Kang J, et al. (2024) Cell-autonomous role of leucine-rich repeat kinase in the protection of dopaminergic neuron survival. *eLife*, 12.
- Dederer V, et al. (2024) A designed ankyrin-repeat protein that targets Parkinson's disease-associated LRRK2. *The Journal of biological chemistry*, 300(7), 107469.
- Ng XY, et al. (2023) Mutations in Parkinsonism-linked endocytic proteins synaptojanin1 and auxilin have synergistic effects on dopaminergic axonal pathology. *NPJ Parkinson's disease*, 9(1), 26.
- Filippini F, et al. (2023) Secretion of VGF relies on the interplay between LRRK2 and post-Golgi v-SNAREs. *Cell reports*, 42(3), 112221.
- Kang J, et al. (2023) Cell autonomous role of leucine-rich repeat kinase in protection of dopaminergic neuron survival. *bioRxiv : the preprint server for biology*.
- He KJ, et al. (2023) LRRK2 G2019S promotes astrocytic inflammation induced by oligomeric α -synuclein through NF- κ B pathway. *iScience*, 26(11), 108130.
- Florio E, et al. (2022) D2R signaling in striatal spiny neurons modulates L-DOPA induced dyskinesia. *iScience*, 25(10), 105263.
- Anantha J, et al. (2022) NME1 Protects Against Neurotoxin-, α -Synuclein- and LRRK2-Induced Neurite Degeneration in Cell Models of Parkinson's Disease. *Molecular neurobiology*, 59(1), 61.
- Bayati A, et al. (2022) Rapid macropinocytic transfer of α -synuclein to lysosomes. *Cell reports*, 40(3), 111102.
- Kedariti M, et al. (2022) LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson's disease. *NPJ Parkinson's disease*, 8(1), 92.